Breast CancerNCT00316836
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
An observational study of Breast Cancer, run by Alliance for Clinical Trials in Oncology at 324 sites in 2 countries.
Trial summary
RATIONALE: Understanding the relationship between breast density, levels of hormones in the blood, and levels of anticancer drugs in the blood may help improve the ability to plan effective treatment for women with invasive breast cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- mammography
- Type of treatment
- Surgery or procedure
- How many people
- 554 participants
- Where
- 324 sitesin 2 countries
- Study dates
- Apr 2006to Feb 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients with diagnosed with breast cancer.
DISEASE CHARACTERISTICS:
- Histologically confirmed invasive breast cancer
- Completely resected disease
- One intact, noncancerous breast with no prior breast surgery in that breast except breast biopsy
- Mammogram available taken within 12 months prior to enrollment that includes side- and top-down views of the intact, noncancerous breast
- Estrogen receptor- and/or progesterone receptor-positive tumor
PATIENT CHARACTERISTICS:
- Female
- Postmenopausal
- Agrees to retrieve and digitize mammograms taken prior to registration (within 12 months prior to atudy entry) and at approximately 1 and 2 years post-registration to this study
- Agrees to have an additional blood banking specimen drawn at the same time as pre-treatment specimens are drawn for parent protocol CAN-NCIC-MA27
- Agrees to have blood sample taken at 12 months post-registration on this study
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 6 months since prior hormone replacement therapy, oral contraceptives, tamoxifen, raloxifene, other selective estrogen-receptor modulators, or gonadotropin releasing-hormone analogues before pre-registration mammogram
Trial locations and contacts
324 sites in 2 countries.
313 sites in 2 countries
United States300 sites
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, 44309-2090
Study site
Alexandria, Minnesota, 56308
AnMed Cancer Center
Anderson, South Carolina, 29621
Augusta Oncology Associates - Walton Way
Augusta, Georgia, 30901
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
Baltimore, Maryland, 21215
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
St. Joseph Cancer Center
Bellingham, Washington, 98225
MeritCare Bemidji
Bemidji, Minnesota, 56601
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704
Mountainview Medical
Berlin Corners, Vermont, 05602
St. Luke's Cancer Network at St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
St. Joseph Medical Center
Bloomington, Illinois, 61701
Bloomington Hospital Regional Cancer Institute
Bloomington, Indiana, 47403
Tufts-NEMC Cancer Center
Boston, Massachusetts, 02111
Massachusetts General Hospital
Boston, Massachusetts, 02114
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Brookdale University Hospital and Medical Center
Brooklyn, New York, 11212
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Peninsula Medical Center
Burlingame, California, 94010
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
St. James Healthcare Cancer Care
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Memorial Hospital
Carthage, Illinois, 62321
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
Rush University Medical Center
Chicago, Illinois, 60612
Resurrection Medical Center
Chicago, Illinois, 60631
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065
Finger Lakes Hematology and Oncology
Clifton Springs, New York, 14432
Kootenai Cancer Center - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Heartland Oncology and Hematology
Council Bluffs, Iowa, 51503
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Grady Memorial Hospital
Delaware, Ohio, 43015
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
St. Luke's Hospital Cancer Care Center
Duluth, Minnesota, 55805
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart General Hospital
Elkhart, Indiana, 46515
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Evanston Northwestern Healthcare - Evanston Hospital
Evanston, Illinois, 60201-1781
Center for Cancer Care at Exeter Hospital
Exeter, New Hampshire, 03833
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
North Bay Cancer Center
Fairfield, California, 94533
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Broadway
Fargo, North Dakota, 58122
Study site
Fergus Falls, Minnesota, 56537
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, 08822
Central Wisconsin Cancer Program at Agnesian HealthCare
Fond du Lac, Wisconsin, 54935
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Kaiser Permanente - Fremont
Fremont, California, 94538
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Delnor Community Hospital - Geneva
Geneva, Illinois, 60134
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California, 91204
Oncology Alliance, SC - Milwaukee - East
Glendale, Wisconsin, 53212-1038
Adirondack Cancer Care - Glens Falls
Glens Falls, New York, 12801
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Metro Health Hospital
Grand Rapids, Michigan, 49506
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
California Cancer Care, Incorporated - Greenbrae
Greenbrae, California, 94904
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Sutter Health - Western Division Cancer Research Group
Greenbrae, California, 94904
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
Mason District Hospital
Havana, Illinois, 62644
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Holland Community Hospital
Holland, Michigan, 49423
New Hampshire Oncology - Hematology, PA - Hooksett
Hooksett, New Hampshire, 03106
Hopedale Medical Complex
Hopedale, Illinois, 61747
Snake River Oncology of Eastern Idaho PLLC
Idaho Falls, Idaho, 83404
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Provena St. Mary's Regional Cancer Center - Kankakee
Kankakee, Illinois, 60901
CCOP - Kansas City
Kansas City, Missouri, 64131
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Kingsbury Center for Cancer Care at Cheshire Medical Center
Keene, New Hampshire, 03431
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Kinston Medical Specialists
Kinston, North Carolina, 28501
Cascade Cancer Center at Evergreen Hospital Medical Center
Kirkland, Washington, 98033
Howard Community Hospital
Kokomo, Indiana, 46904
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Haematology-Oncology Associates of Ohio and Michigan, PC
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
Cleo Craig Cancer Research Clinic
Lawton, Oklahoma, 73505
Central Maine Comprehensive Cancer Center at Central Maine Medical Center
Lewiston, Maine, 04240
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Central Baptist Hospital
Lexington, Kentucky, 40503-9985
Southwest Medical Center
Liberal, Kansas, 67901
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
St. Barnabas Medical Center Cancer Center
Livingston, New Jersey, 07039
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90089-9181
James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
McDonough District Hospital
Macomb, Illinois, 61455
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Elliot Regional Cancer Center at Elliot Hospital
Manchester, New Hampshire, 03103
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Marlton, New Jersey, 08053
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Northwest Ohio Oncology Center
Maumee, Ohio, 43537
St. Luke's Hospital
Maumee, Ohio, 43537
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53201-0342
Medical Consultants, Limited
Milwaukee, Wisconsin, 53215
Community Medical Center
Missoula, Montana, 59801
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Carol G. Simon Cancer Center at Morristown Memorial Hospital
Morristown, New Jersey, 07962
Community Hospital
Munster, Indiana, 46321
Hackley Hospital
Muskegon, Michigan, 49442
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Advocate Christ Medical Center
Oak Lawn, Illinois, 60453-2699
Kaiser Permanente Medical Center - Oakland
Oakland, California, 94611
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
Oklahoma University Cancer Institute
Oklahoma City, Oklahoma, 73104
Cancer Care Associates - Mercy Campus
Oklahoma City, Oklahoma, 73120
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Estabrook Cancer Center
Omaha, Nebraska, 68114
Immanuel Medical Center
Omaha, Nebraska, 68122
Alegant Health Cancer Center at Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Creighton University Medical Center
Omaha, Nebraska, 68131-2197
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Toledo Clinic - Oregon
Oregon, Ohio, 43616
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois, PC - Ottawa
Ottawa, Illinois, 61350
McCreery Cancer Center at Ottumwa Regional
Ottumwa, Iowa, 52501
Desert Regional Medical Center Comprehensive Cancer Center
Palm Springs, California, 92262
Cancer Center of Paoli Memorial Hospital
Paoli, Pennsylvania, 19301-1792
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
NSMC Cancer Center - Peabody
Peabody, Massachusetts, 01960
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
West Florida Cancer Institute at West Florida Hospital - Pensacola
Pensacola, Florida, 32514
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Warren Hospital
Phillipsburg, New Jersey, 08865
Cancer Center at Phoenixville Hospital
Phoenixville, Pennsylvania, 19460
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
Pinehurst, North Carolina, 28374
Olympic Medical Center
Port Angeles, Washington, 98362
Mercy Hospital
Portland, Maine, 04101
Pottstown Memorial Regional Cancer Center
Pottstown, Pennsylvania, 19464
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
All Saints Cancer Center at Wheaton Franciscan Healthcare
Racine, Wisconsin, 53405
Kaiser Permanente Medical Center - Redwood City
Redwood City, California, 94063
Valley Medical Center
Renton, Washington, 98055
Kaiser Permanente Medical Center - Richmond
Richmond, California, 94801
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Swedish-American Regional Cancer Center
Rockford, Illinois, 61104-2315
Kaiser Permanente Medical Center - Roseville
Roseville, California, 95661
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
Rutherford Hospital
Rutherfordton, North Carolina, 28139
South Sacramento Kaiser-Permanente Medical Center
Sacramento, California, 95823
Kaiser Permanente Medical Center - Sacramento
Sacramento, California, 95825
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
Lakeland Regional Cancer Care Center - St. Joseph
Saint Joseph, Michigan, 49085
Oncology Care Associates, PLLC
Saint Joseph, Michigan, 49085
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67042
Kaiser Permanente Medical Center - San Francisco Geary Campus
San Francisco, California, 94115
California Pacific Medical Center - California Campus
San Francisco, California, 94118
Kaiser Permanente Medical Center - Santa Teresa
San Jose, California, 95119
Kaiser Foundation Hospital - San Rafael
San Rafael, California, 94903
Firelands Regional Medical Center
Sandusky, Ohio, 44870
North Coast Cancer Care, Incorporated
Sandusky, Ohio, 44870
Kaiser Permanente Medical Center - Santa Clara Kiely Campus
Santa Clara, California, 95051
Kaiser Permanente Medical Center - Santa Rosa
Santa Rosa, California, 95403
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95405
Guthrie Cancer Center at Guthrie Clinic Sayre
Sayre, Pennsylvania, 18840
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259-5499
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
Group Health Central Hospital
Seattle, Washington, 98112
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195-6043
Welch Cancer Center at Sheridan Memorial Hospital
Sheridan, Wyoming, 82801
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Saint Joseph Regional Medical Center
South Bend, Indiana, 46617
Kaiser Permanente Medical Center - South San Francisco
South San Francisco, California, 94080
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
St. Margaret's Hospital
Spring Valley, Illinois, 61362
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Mercy Medical Center
Springfield, Ohio, 45504
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
St Louis, Missouri, 63110
Geisinger Medical Group - Scenery Park
State College, Pennsylvania, 16801
Mount Nittany Medical Center
State College, Pennsylvania, 16803
Kaiser Permanente Medical Facility - Stockton
Stockton, California, 95210
Green Bay Oncology, Limited - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
Overlook Hospital
Summit, New Jersey, 07902
Flower Hospital Cancer Center
Sylvania, Ohio, 43560
CCOP - Scott and White Hospital
Temple, Texas, 76508
Albert Einstein Cancer Center at Albert Einstein College of Medicine
The Bronx, New York, 10461
Mercy Hospital of Tiffin
Tiffin, Ohio, 44883
Toledo Hospital
Toledo, Ohio, 43606
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
CCOP - Toledo Community Hospital
Toledo, Ohio, 43617
Toledo Clinic, Incorporated - Main Clinic
Toledo, Ohio, 43623
Munson Medical Center
Traverse City, Michigan, 49684
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Kaiser Permanente Medical Center - Vallejo
Vallejo, California, 94589
Sutter Solano Medical Center
Vallejo, California, 94589
Fox Chase Virtua Health Cancer Program at Virtua West Jersey
Voorhees Township, New Jersey, 08043
Kaiser Permanente Medical Center - Walnut Creek
Walnut Creek, California, 94596
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016
Cedar Valley Medical Specialists, PC - West Ridgeway Avenue
Waterloo, Iowa, 50702
Covenant Cancer Treatment Center
Waterloo, Iowa, 50702
University of Wisconcin Cancer Center at Aspirus Wausau Hospital
Wausau, Wisconsin, 54401
Fulton County Health Center
Wauseon, Ohio, 43567
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Chester County Hospital
West Chester, Pennsylvania, 19380
Mount Carmel St. Ann's Cancer Center
Westerville, Ohio, 43081
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Canada13 sites
Cambridge Memorial Hospital
Cambridge, Ontario, N1R 3G2
Hopital Charles Lemoyne
Greenfield Park, Quebec, J4V 2H1
Moncton Hospital
Moncton, New Brunswick, E1C 6Z8
Hopital du Saint-Sacrement - Quebec
Québec, Quebec, G1S 4L8
Allan Blair Cancer Centre at Pasqua Hospital
Regina, Saskatchewan, S4T 7T1
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Algoma District Cancer Program at Sault Area Hospital
Sault Ste. Marie, Ontario, P6A 2C4
Cancer Care Program at Thunder Bay Regional Health Sciences
Thunder Bay, Ontario, P7B 6V4
Edmond Odette Cancer Centre at Sunnybrook
Toronto, Ontario, M4N 3M5
St. Michael's Hospital - Toronto
Toronto, Ontario, M5B 1W8
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
British Columbia Cancer Agency - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
About this study
Official title: The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27
RATIONALE: Understanding the relationship between breast density, levels of hormones in the blood, and levels of anticancer drugs in the blood may help improve the ability to plan effective treatment for women with invasive breast cancer.
PURPOSE: This clinical trial is studying the relationship between breast density and blood levels of hormones and anticancer drugs in women with invasive breast cancer who are receiving exemestane or anastrozole.
Read the detailed description
OBJECTIVES:
Primary
- Assess the change in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year, 1 year to 2 years, and pretreatment to 2 years in women with invasive breast cancer.
- Determine the changes in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year and correlate the changes with changes in plasma hormones (e.g., estrone, estrone-sulfate, estradiol, and sex hormone binding globulin) and drug levels (anastrozole or exemestane) over the same period in women with invasive breast cancer.
- Determine the change over time in percent breast density and dense area (from pretreatment to the time period prior to local recurrence) in the contralateral breast in correlation to local recurrence of breast cancer.
Secondary
- Determine the change over time in percent breast density and dense area in the contralateral breast in correlation to the development of contralateral breast cancer.
- Determine whether women with high pretreatment percent density (upper tertile) experience greater decreases in percent breast density at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment percent density (lower tertile).
- Determine whether women with high pretreatment dense area (upper tertile) experience greater decreases in dense area at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment dense area (lower tertile).
- Correlate haplotype tagged single nucleotide polymorphisms in genes in the aromatase pathway (identified thorough the Mayo Clinic and Indiana University Pharmacogenomics Research Network Projects) with changes in percent and area breast density, plasma hormone levels, and 1-year drug levels.
OUTLINE: This is a multicenter, companion study.
Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
PROJECTED ACCRUAL: A total of 550 patients will be accrued for this study.
- Conditions
- Breast Cancer
- Being tested
- mammography
- Keywords
- stage I breast cancer, stage II breast cancer, stage IIIA breast cancer
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mammographyProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area. Receives: Procedure: mammography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in breast density measured by percent and area at 1 and 2 years
Measured: Up to 2 years
Correlation of changes in breast density with plasma hormones and drug levels measured by estrone, estrone-sulfate, estradiol, sex hormone binding globulin, anastrozole, or exemestane levels at 1 and 2 years
Measured: Up to 2 years
Secondary outcomes (1)
Correlation of breast density with contralateral breast cancers at 1 and 2 years
Measured: Up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2006 (estimated)
- Study startApr 2006
- Primary completionOct 2010
- Study completionFeb 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 554 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), NCIC Clinical Trials Group
- Responsible party
- Sponsor
- Investigators
- James N. Ingle, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00316836
- Sponsor's protocol ID
- NCCTG-N0434
- Other IDs
- NCCTG-N0434, CAN-NCIC-MA27D, CDR0000462330
- Status last verified
- Jan 2019
- First submitted
- 19 Apr 2006
- Last updated
- 24 Jan 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27
- ClinicalTrials.gov ID
- NCT00316836
- Acronym / sponsor ID
- NCCTG-N0434
- Conditions
- Breast Cancer
- Keywords
- stage I breast cancer, stage II breast cancer, stage IIIA breast cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 554 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), NCIC Clinical Trials Group
- Study start
- Apr 2006
- Primary completion
- Oct 2010 (actual)
- Study completion
- Feb 2012 (actual)
- First posted
- 21 Apr 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Understanding the relationship between breast density, levels of hormones in the blood, and levels of anticancer drugs in the blood may help improve the ability to plan effective treatment for women with invasive breast cancer.
PURPOSE: This clinical trial is studying the relationship between breast density and blood levels of hormones and anticancer drugs in women with invasive breast cancer who are receiving exemestane or anastrozole.
Detailed description
OBJECTIVES:
Primary
- Assess the change in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year, 1 year to 2 years, and pretreatment to 2 years in women with invasive breast cancer.
- Determine the changes in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year and correlate the changes with changes in plasma hormones (e.g., estrone, estrone-sulfate, estradiol, and sex hormone binding globulin) and drug levels (anastrozole or exemestane) over the same period in women with invasive breast cancer.
- Determine the change over time in percent breast density and dense area (from pretreatment to the time period prior to local recurrence) in the contralateral breast in correlation to local recurrence of breast cancer.
Secondary
- Determine the change over time in percent breast density and dense area in the contralateral breast in correlation to the development of contralateral breast cancer.
- Determine whether women with high pretreatment percent density (upper tertile) experience greater decreases in percent breast density at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment percent density (lower tertile).
- Determine whether women with high pretreatment dense area (upper tertile) experience greater decreases in dense area at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment dense area (lower tertile).
- Correlate haplotype tagged single nucleotide polymorphisms in genes in the aromatase pathway (identified thorough the Mayo Clinic and Indiana University Pharmacogenomics Research Network Projects) with changes in percent and area breast density, plasma hormone levels, and 1-year drug levels.
OUTLINE: This is a multicenter, companion study.
Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
PROJECTED ACCRUAL: A total of 550 patients will be accrued for this study.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | Procedure: mammographyPatients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with diagnosed with breast cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mammography | Procedure or surgery | Group 1 |
Primary outcome
Changes in breast density measured by percent and area at 1 and 2 years
Time frame: Up to 2 years
Correlation of changes in breast density with plasma hormones and drug levels measured by estrone, estrone-sulfate, estradiol, sex hormone binding globulin, anastrozole, or exemestane levels at 1 and 2 years
Time frame: Up to 2 years
1 secondary outcome
Correlation of breast density with contralateral breast cancers at 1 and 2 years
Time frame: Up to 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jan 2019.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James N. Ingle, MD study chair
Mayo Clinic
324 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer, run by Alliance for Clinical Trials in Oncology at 324 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 324 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in breast density measured by percent and area at 1 and 2 years (time frame: Up to 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2019.